Keyword: CytomX Therapeutics
Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.
CytomX's R&D update includes the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price.
Pfizer is backing out of its $635 million armed antibody tech deal with CytomX.
CytomX signed a biobucks deal potentially worth $1.5 billion with Amgen.
Bryan Irving made his name in a decadelong stint at Genentech, during which he performed research that gave rise to anti-PD-L1 antibody Tecentriq.
Fierce 15 winner CytomX is in line for a $200 million upfront payday and potentially billions in biobucks from partner Bristol-Myers Squibb as the Big Pharma signs a deal on eight additional targets using CytomX’s Probody platform.